{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"4.4","upperLimit":"17.5","value":"6.7"},{"comment":"Only 1 participant had PR, therefore 95% Confidence Interval was not calculable.","groupId":"OG001","lowerLimit":"NA","upperLimit":"NA","value":"6.0"},{"comment":"Median and the upper 95% confidence interval was not achieved due to high censoring rate.","groupId":"OG002","lowerLimit":"9.7","upperLimit":"NA","value":"NA"},{"comment":"Median and the upper 95% confidence interval was not achieved due to high censoring rate.","groupId":"OG003","lowerLimit":"11.1","upperLimit":"NA","value":"NA"},{"groupId":"OG004","lowerLimit":"4.6","upperLimit":"16.8","value":"8.3"},{"comment":"Median and the upper 95% confidence interval was not achieved due to high censoring rate.","groupId":"OG005","lowerLimit":"5.2","upperLimit":"NA","value":"NA"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"7"},{"groupId":"OG003","value":"8"},{"groupId":"OG004","value":"3"},{"groupId":"OG005","value":"11"}],"units":"Participants"}],"description":"The duration of response is defined only for responders (patients with a confirmed CR or PR). It is measured from the date of first evidence of a confirmed CR or PR to the date of objective progression or the date of death due to any cause, whichever is earlier. If a responder is not known to have died or have objective progression as of the data inclusion cutoff date, DoR will be censored at the date of the last complete objective progression-free disease assessment (CR or PR) was defined as the time from first objective status assessment of CR or PR to the first time of progression or death as a result of any cause.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants with Gastric-GEJ cancer (Second-Third L) received 8 mg/kg ramucirumab given IV on day 1 and 8 in combination with 200 mg pembrolizumab given IV on day 1 Q3W of a 21-day cycle in Cohort A.\n\nParticipants with Gastric-GEJ cancer (Second-Third L) received 10 mg/kg ramucirumab given IV on day 1 in combination with 200 mg pembrolizumab given IV on day 1 Q3W of a 21-day cycle in Cohort B.","id":"OG000","title":"Cohort A and B"},{"description":"Participants with BTC cancer (Second-Third L) received 8 mg/kg ramucirumab given IV on day 1 and 8 in combination with 200 mg pembrolizumab given IV on day 1 Q3W of a 21-day cycle.","id":"OG001","title":"Cohort A1"},{"description":"Participants with Gastric-GEJ cancer (First L) received 8 mg/kg ramucirumab given IV on day 1 and 8 in combination with 200 mg pembrolizumab given IV on day 1 Q3W of a 21-day cycle.","id":"OG002","title":"Cohort A2"},{"description":"Participants with NSCLC (Second-Fourth L) received 10 mg/kg ramucirumab given IV on day 1 in combination with 200 mg pembrolizumab given IV on day 1 Q3W of a 21-day cycle.","id":"OG003","title":"Cohort C"},{"description":"Participants with Urothelial cancer (Second-Fourth L) received 10 mg/kg ramucirumab given IV on day 1 in combination with 200 mg pembrolizumab given IV on day 1 Q3W of a 21-day cycle.","id":"OG004","title":"Cohort D"},{"description":"Participants with NSCLC cancer (First L) received 10 mg/kg ramucirumab given IV on day 1 in combination with 200 mg pembrolizumab given IV on day 1 Q3W of a 21-day cycle.","id":"OG005","title":"Cohort E"}],"paramType":"MEDIAN","populationDescription":"All enrolled participants who received at least one dose of the study drug. Per Protocol, Cohort A and B participants \\[Gastric-GEJ cancer (Second-Third L)\\] were combined and outcome data was analyzed under a single arm (Cohort A and B).","reportingStatus":"POSTED","timeFrame":"Date of CR or PR to Date of Objective Disease Progression or Death Due to Any Cause (Up to 24 Months)","title":"Phase 1a and 1b: Duration of Response (DoR)","type":"SECONDARY","unitOfMeasure":"months"}